Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company based in Foster City, California. The company employs 337 individuals and generates approximately $100 million in annual revenue. Mirum Pharmaceuticals is dedicated to developing and commercializing treatments for rare diseases that affect both children and adults. The company currently markets three approved medications: LIVMARLI (maralixibat) oral solution, CHOLBAM (cholic acid) capsules, and CHENODAL (chenodiol) tablets. LIVMARLI is an IBAT inhibitor approved for treating cholestatic pruritus in patients with Alagille syndrome and PFIC (progressive familial intrahepatic cholestasis). CHOLBAM is FDA-approved for treating bile acid synthesis disorders and adjunctive treatment of peroxisomal disorders. CHENODAL has received medical necessity recognition from the FDA to treat patients with cerebrotendinous xanthomatosis (CTX). Mirum's research and development pipeline includes two late-stage investigational treatments for debilitating liver diseases. Volixibat, another IBAT inhibitor, is being evaluated in clinical trials for primary sclerosing cholangitis and primary biliary cholangitis. CHENODAL is also undergoing further clinical testing for the treatment of CTX. For more information, visit mirumpharma.com.